Vascular endothelial growth factor-2 gene therapy - Corautus Genetics

Drug Profile

Vascular endothelial growth factor-2 gene therapy - Corautus Genetics

Alternative Names: VEGF-2 gene therapy - Corautus Genetics

Latest Information Update: 11 Jun 2007

Price : $50

At a glance

  • Originator Human Genome Sciences
  • Developer Boston Scientific Corporation
  • Class Cytokine genes; Gene therapies; Growth factors
  • Mechanism of Action Angiogenesis inducing agents
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

  • New Molecular Entity No

Highest Development Phases

  • Suspended Angina pectoris; Coronary artery restenosis; Diabetic neuropathies; Ischaemic heart disorders; Vascular disorders

Most Recent Events

  • 06 Jun 2007 Corautus Genetics has been acquired and merged into VIA Pharmaceuticals
  • 03 Nov 2006 Suspended - Phase-II for Vascular disorders in USA (Parenteral)
  • 03 Nov 2006 Suspended - Phase-II for Ischaemic heart disorders in USA (Intracoronary)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top